News >

Celgene, Juno Ink $1 Billion Immunotherapy Deal

Silas Inman @silasinman
Published: Tuesday, Jun 30, 2015

Bob Hugin

Bob Hugin

CEO of Celgene

Celgene has entered into a 10-year collaboration with the cellular immunotherapy company Juno Therapeutics, which includes an initial billion payment, according to a joint statement released by the companies.

Celgene has a number of already approved therapies for patients with hematologic malignancies and other types of cancer, including pomalidomide, lenalidomide, azacitidine, romidepsin, and nab-paclitaxel. Additionally, the company has a broad research pipeline.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Publication Bottom Border
Border Publication
x